CTLA4 and neoplasm: For instance, ECM glycoprotein alterations may foster a tumor-supportive niche [37,38], while immune dysregulation—marked by upregulated checkpoint molecules such as PD-L1 and CTLA-4—could enable tumor cells to escape immune surveillance [39,40].